Overview

Efficacy of Resveratrol in Depression

Status:
Completed

Trial end date:
2019-09-18

Target enrollment:

Participant gender:

Summary

Patients with depression (target number - 60) receive resveratrol 500 mg or placebo (1:1) each morning daily for 1 month with primary outcome measures of the score change on depression rating scale HDRS-17 and change in SIRT1 activity in the blood measured 4 times over the study period (before, in the middle, after the intervention, and in 2 week follow up).

Phase:

Phase 4

Details

Lead Sponsor:

Russian Academy of Medical Sciences

Collaborator:

Russian Science Foundation

Treatments:

Resveratrol